Relay Therapeutics (RLAY) Stock: Buy, Sell, or Hold?
RLAY - Relay Therapeutics, Inc. Common Stock
$18.25
1.16 (6.76%)
▲
5d:
+5.1%
30d:
+0.3%
90d:
-5.32%
BUY
HIGH Confidence
Analysis Updated: Oct 20, 2026 12:00 AM ET
Earnings: Nov 05, 2026
15d
Get Alerted When RLAY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: RLAY shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: RLAY shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: RLAY is currently trading at $18.25, which is considered fair relative to its 30-day fair value range of $17.40 to $18.95.
Technical Outlook: Technically, RLAY is in a uptrend. The price is approaching resistance at $18.57. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.8% recently.
Market Sentiment: RLAY scores 72/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $27.58 (+61.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, RLAY is in a uptrend. The price is approaching resistance at $18.57. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.8% recently.
Market Sentiment: RLAY scores 72/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $27.58 (+61.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$17.40 -
$18.95
Company Quality Score
60/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
92.1%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (72/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+6.8%)
- BULLISH: Trading 61.4% below Wall St target ($27.58)
- BULLISH: Bottoming setup score 72/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$17.40 -
$18.95
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$16.13
Resistance Level
$18.57
Current Trend
Uptrend
Technical data as of
Oct 20, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-10.47
Wall Street Target
$27.58
(+61.4%)
Revenue Growth (YoY)
-48.3%
Share & Embed Analysis
Last updated: October 20, 2026 1:05 PM ET
Data refreshes hourly during market hours. Next update: 2:05 PM
Data refreshes hourly during market hours. Next update: 2:05 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RLAY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
28 analysts |
$92 | 73 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
20 analysts |
$36 | 67 BUY |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
18 analysts |
$70 | 67 BUY |
|
WVE
Wave Life Sciences Ltd |
STRONG BUY
20 analysts |
$17 | 60 BUY |
|
ARWR
Arrowhead Pharmaceutical… |
STRONG BUY
15 analysts |
$108 | 73 BUY |
